Article Text

Download PDFPDF
Treatment dependence in chronic inflammatory demyelinating polyradiculoneuropathy: is it related to disease phenotype or to the therapy used?
  1. Eduardo Nobile-Orazio
  1. Correspondence to Professor Eduardo Nobile-Orazio, Department of Medical Biotechnology and Translational Medicine (BIOMETRA), University of Milan, 2nd Neurology, IRCCS Humanitas Clinical Institute, Via Manzoni 56, Rozzano, Milan 20089, Italy; eduardo.nobile{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and disabling immune neuropathy which often has a heterogeneous presentation. Patients usually improve after therapy with steroids, high-dose intravenous immunoglobulin (IVIg) or plasma exchange. Most patients require, however, a prolonged treatment to avoid deterioration. It is unclear which therapy should be first used in these patients and whether there are clues to predict for how long therapy should be continued. Rabin et al1 reviewed the data from 70 patients with CIDP who had responded to therapy and compared the clinical, electrophysiological and laboratory data of 36 patients who could suspend therapy without deterioration (treatment withdrawal) with those of 34 patients who needed to continue the therapy to avoid deterioration (treatment dependent).

The authors found …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles